S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders

Protagonist Therapeutics (PTGX) News Headlines

$11.46
-0.25 (-2.13%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$11.02
$11.83
50-Day Range
$7.06
$11.71
52-Week Range
$6.91
$50.54
Volume
831,004 shs
Average Volume
1.01 million shs
Market Capitalization
$557.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.63
Get Protagonist Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.

PTGX Media Mentions By Week

PTGX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PTGX
News Sentiment

1.50

0.34

Average
Medical
News Sentiment

PTGX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PTGX Articles
This Week

2

1

PTGX Articles
Average Week



SourceHeadline
marketbeat.com logoProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of "Moderate Buy" from Analysts
marketbeat.com - August 6 at 1:47 AM
MarketBeat logoProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $50.63 Consensus PT from Analysts
americanbankingnews.com - July 15 at 2:32 AM
seekingalpha.com logoMGNI, NRIX and PTGX are among after hour and movers
seekingalpha.com - June 4 at 5:02 AM
seekingalpha.com logoProtagonist Therapeutics (PTGX) Presents at Digestive Disease Week (DDW) 2022
seekingalpha.com - June 2 at 11:53 PM
finance.yahoo.com logoProtagonist Therapeutics to Participate at the Jefferies Healthcare Conference
finance.yahoo.com - June 1 at 4:49 PM
finance.yahoo.com logoA new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?
finance.yahoo.com - May 26 at 5:20 PM
finance.yahoo.com logoProtagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
finance.yahoo.com - May 26 at 5:20 PM
seekingalpha.com logoPTGX, MNKD and AVGO are among after hour movers
seekingalpha.com - May 20 at 11:54 PM
finance.yahoo.com logo7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
finance.yahoo.com - May 19 at 2:00 AM
finance.yahoo.com logoIndustry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
finance.yahoo.com - May 11 at 10:56 AM
nz.finance.yahoo.com logoShareholders in Protagonist Therapeutics (NASDAQ:PTGX) are in the red if they invested a year ago
nz.finance.yahoo.com - May 4 at 1:49 PM
apnews.com logoROSEN, RESPECTED INVESTOR COUNSEL, Encourages Protagonist Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – PTGX
apnews.com - April 26 at 6:22 PM
finance.yahoo.com logoProtagonist Therapeutics shares slid after sharing Phase 2 data for its experimental ulcerative colitis treatment
finance.yahoo.com - April 26 at 1:09 PM
apnews.com logoProtagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
apnews.com - April 25 at 5:06 PM
apnews.com logoOngoing Investigation Notice: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
apnews.com - April 25 at 12:04 PM
apnews.com logoINVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
apnews.com - April 21 at 11:58 AM
apnews.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protagonist Therapeutics, Inc. - PTGX
apnews.com - April 20 at 2:02 AM
seekingalpha.com logoHot Stocks: CXW hits high on upgrade; CMBM plunges; VALN, PTGX move on regulatory decisions
seekingalpha.com - April 14 at 11:03 PM
finance.yahoo.com logoWhy this East Bay biotech lost nearly 22% of its value
finance.yahoo.com - April 14 at 11:03 PM
msn.com logoThe Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
msn.com - April 14 at 1:03 PM
seekingalpha.com logoProtagonist down 22% after FDA plans to rescind Breakthrough Therapy designation for rusfertide
seekingalpha.com - April 14 at 1:03 PM
finance.yahoo.com logoProtagonist's stock falls 27% after updating investors about experimental blood disorder drug
finance.yahoo.com - April 14 at 1:03 PM
finance.yahoo.com logoProtagonist Therapeutics Dives As Its Drama Continues With A New FDA Concern
finance.yahoo.com - April 14 at 1:03 PM
uk.investing.com logoFDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood Cancer
uk.investing.com - April 14 at 8:02 AM
seekingalpha.com logoAsif Ali is the new finance chief at Protagonist Therapeutics
seekingalpha.com - March 28 at 9:58 AM
finance.yahoo.com logoProtagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer
finance.yahoo.com - March 28 at 9:58 AM
seekingalpha.com logoBiondVax, Alpha Tau top healthcare gainers; Sonendo, Creative Medical among losers
seekingalpha.com - March 25 at 9:33 PM
finance.yahoo.com logoProtagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis
finance.yahoo.com - March 24 at 5:17 AM
nasdaq.com logoProtagonist Gets $25 Mln Milestone Payment From Janssen
nasdaq.com - March 16 at 11:21 AM
finance.yahoo.com logoProtagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
finance.yahoo.com - February 28 at 5:10 PM
finance.yahoo.com logo3 Desirable Drug Stocks With Very Promising Pipelines
finance.yahoo.com - February 24 at 7:57 AM
finance.yahoo.com logoProtagonist Therapeutics (PTGX) Soars 5%: Is Further Upside Left in the Stock?
finance.yahoo.com - February 16 at 7:39 AM
nasdaq.com logoNotable Tuesday Option Activity: PTGX, TTCF, PANW
nasdaq.com - February 15 at 4:37 PM
benzinga.com logoBTIG Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $55
benzinga.com - February 11 at 6:26 PM
finance.yahoo.com logoProtagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 10 at 3:59 PM
nasdaq.com logoFirst Week of PTGX February 18th Options Trading
nasdaq.com - February 7 at 6:55 PM
finance.yahoo.com logoWe're Hopeful That Protagonist Therapeutics (NASDAQ:PTGX) Will Use Its Cash Wisely
finance.yahoo.com - February 7 at 6:55 PM
nasdaq.com logoWe Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
nasdaq.com - January 4 at 3:31 PM
finance.yahoo.com logo/C O R R E C T I O N -- Protagonist Therapeutics, Inc./
finance.yahoo.com - January 4 at 3:31 PM
finance.yahoo.com logoProtagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting
finance.yahoo.com - December 12 at 10:00 AM
markets.businessinsider.com logoThe Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
markets.businessinsider.com - December 3 at 7:57 AM
finance.yahoo.com logoProtagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summit
finance.yahoo.com - December 3 at 7:57 AM
benzinga.com logoWhat 9 Analyst Ratings Have To Say About Protagonist Therapeutics
benzinga.com - November 15 at 5:50 PM
finance.yahoo.com logoProtagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis
finance.yahoo.com - November 15 at 7:49 AM
finance.yahoo.com logoProtagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
finance.yahoo.com - November 11 at 8:27 AM
finance.yahoo.com logoProtagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting
finance.yahoo.com - November 4 at 11:21 AM
finance.yahoo.com logoHedge Funds Are Crazy About Protagonist Therapeutics, Inc. (PTGX)
finance.yahoo.com - October 18 at 6:37 AM
finance.yahoo.com logoJ.P. Morgan Says There’s Room for Over 40% Upside in These 2 Stocks
finance.yahoo.com - October 13 at 10:20 PM
markets.businessinsider.com logoAnalyst Ratings For Protagonist Therapeutics
markets.businessinsider.com - October 12 at 3:23 PM
markets.businessinsider.com logoWhere Protagonist Therapeutics Stands With Analysts
markets.businessinsider.com - October 11 at 1:37 PM
finance.yahoo.com logoProtagonist Stock Flashes This Positive Signal After FDA Lifts Hold On Blood Diseases Drug
finance.yahoo.com - October 11 at 1:37 PM
Get Protagonist Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:PTGX) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.